Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$12.69 USD
+0.27 (2.17%)
Updated May 31, 2024 04:00 PM ET
After-Market: $12.61 -0.08 (-0.63%) 4:54 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 81 - 100 ( 145 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; ReSPECT Trial Gears up; ReSTORE Remains on Track
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Covered Companies'' ASM Schedules, Additional Sessions and Abstracts of Interest
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Rezafungin on Track for Ph 3 Initiations with Recent Financing
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Additional STRIVE Analyses Confirm Support for Ph 3 Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q Recap: Phase 3 Studies for Treatment and Prophylaxis of Rezafungin to Start in 2018; PT to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; FDA Supports Expedited Ph 3 Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - ID Week Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Week Ahead
Provider: WEDBUSH SECURITIES INC.